Genmab A/S Files 6-K for S-8 Registration Statements
Ticker: GNMSF · Form: 6-K · Filed: Oct 15, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, registration-statement, stock-compensation
TL;DR
Genmab filed a 6-K, mostly boilerplate for stock plans. No major news.
AI Summary
Genmab A/S filed a Form 6-K on October 15, 2024, to be incorporated by reference into its existing S-8 registration statements. These statements relate to the company's stock-based compensation plans, specifically referencing file numbers 333-232693, 333-253519, 333-262970, and 333-277273.
Why It Matters
This filing is procedural and relates to the company's ongoing stock compensation plans, indicating continued equity-based incentives for employees.
Risk Assessment
Risk Level: low — This is a routine administrative filing related to existing stock registration statements and does not contain new financial or operational information.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (dollar_amount) — S-8 Registration Statement File Number
- 333-253519 (dollar_amount) — S-8 Registration Statement File Number
- 333-262970 (dollar_amount) — S-8 Registration Statement File Number
- 333-277273 (dollar_amount) — S-8 Registration Statement File Number
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The Form 6-K is being filed to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
What are Form S-8 registration statements typically used for?
Form S-8 registration statements are used by companies to register securities to be offered to employees pursuant to employee benefit plans.
When was this Form 6-K filed?
This Form 6-K was filed on October 15, 2024.
Does this filing introduce new financial information for Genmab A/S?
No, this filing is primarily for administrative purposes, incorporating previous information into existing registration statements, and does not appear to introduce new financial data.
What is the principal executive office address for Genmab A/S?
The principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 227 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2024-10-15 10:34:32
Filing Documents
- tmb-20241015x6k.htm (6-K) — 18KB
- tmb-20241015xex99d1.htm (EX-99.1) — 19KB
- tmb-20241015xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-013308.txt ( ) — 45KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: October 15, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated October 15, 2024: Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2024